Homzygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort

STEVEN LEHRER1 and PETER H. RHEINSTEIN2

1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.; 2Severn Health Solutions, Severna Park, MD, U.S.A.

Abstract. Background/Aim: Adult outpatients with symptomatic COVID-19 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. Fluvoxamine strongly binds to the sigma-1 receptor (S1R) that regulates inflammation by inhibiting the production of cytokines, believed to be responsible for severe COVID-19. We evaluated the S1R locus on chr 9p13.3 in subjects tested positive for SARS-CoV-2. We focused on SNP rs17775810 that has been previously identified by examining loss-of-function mutations in the S1R gene associated with distal hereditary motor neuropathy. Patients and Methods: We utilized UK Biobank (UKB) data. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6, at the Icahn School of Medicine at Mount Sinai. Results: The effect of rs17775810 genotype on survival was significant (p=0.036, 2 tailed Fisher exact test). The minor allele homozygotes (TT) had the lowest death rate (0%), whereas the non-TT genotypes (i.e. CT and CC) had the highest death rate (16.2%). Conclusion: The rs17775810 analysis corroborates the favorable effect of fluvoxamine on COVID-19 survival.

In a preliminary study, adult outpatients with symptomatic COVID-19 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. Fluvoxamine strongly binds to the sigma-1 receptor (SIR) that regulates inflammation by inhibiting the production of cytokines, believed to be responsible for severe COVID-19 (1). The S1R receptor is a ubiquitously expressed endoplasmic reticulum (ER) chaperone protein located mainly at the ER membrane rather than predominantly on the plasma membrane of cells. The S1R receptor is expressed in many types of cells, not only immune cells, and can detach from the ER membrane and function in the ER lumen, chaperoning other proteins through the ER.

Patients and Methods

We utilized data from the UK Biobank (UKB). The UKB databases consist of data obtained from >500,000 community volunteers between 40-70 years of age at baseline (2006-2010), residing close to 22 assessment centers in the UK, Scotland and Wales. Baseline assessments on the database include demographics, the lifestyle of the subjects and the disease history of the subjects, with links available leading to electronic medical records. The UKB application for the present study was approved as UKB project 57245 (S.L. and P.H.R.) (2).

To investigate the relationship between S1R and COVID-19, we evaluated the S1R locus on chr 9p13.3 in subjects tested positive for SARS-CoV-2. We analysed the SNP rs17775810. This SNP has previously identified loss-of-function mutations in the S1R gene causing distal hereditary motor neuropathy (3) linked to an area including two SNPs: rs17775810, analyzed here, and one other not in UKB, which covered an area of 7.9 Mb. rs17775810 has a single nucleotide variation, C>T, with minor allele (T) frequency=0.21.

Data processing was performed on Minerva, a Linux mainframe with Centos 7.6, at the Icahn School of Medicine at Mount Sinai. We used PLINK, a whole-genome association analysis toolset, to process the UKB chromosome 9 files, and the UK Biobank Data Parser (ukbb parser), a python-based package that allows easy interfacing with the large UKB dataset (4).

Results

We evaluated the association of the rs17775810 genotypes with survival of COVID-19 patients and designated the major rs17775810 allele as C and the minor allele as T. We analyzed data from 688 UKB subjects with laboratory confirmed COVID-19, 49% female, 51% male. The mean
age was 54±9.2 (mean±SD). One hundred eight (16%) had died of COVID-19. Among the subjects, 83% were white British, 3% were Irish, 3% were of any other white background, 2% were African, 2% were Caribbean, 7% were of other ethnicity.

COVID-19 survival according to the different genotypes (TT homozygote versus non-TT) is shown in Table I. The effect of each genotype on survival was significant (p=0.036, 2 tailed Fisher exact test). The TT homozygotes had the lowest death rate (0%), whereas the non-TT genotypes (i.e. CT and CC) had the highest death rate (16.2%).

COVID-19 survival according to the rs17775810 genotype (TT versus CT and CC) is shown in Table II. The TT homozygotes had the lowest death rate (0%, p=0.020, likelihood ratio).

**Discussion**

Genome-wide association studies have found multiple genes and loci that increase the risk of respiratory failure in COVID-19 (5). One locus on chromosome 3p21.31 contains 6 genes involved in inflammation (SLC6A20, LZTFL1, CCR9, TYCO1, CXCR6, and XCR1) (5).

The ABO gene, chr 9q34.2, which determines blood type, may affect disease severity. Corrected for age and sex, a higher risk for respiratory failure was found among persons with blood group A than among patients with other blood groups, and a protective effect for blood group O as compared with the other blood groups (5). However, this result has not been reproduced. A UK study of 2200 COVID-19 patients found no relationship of ABO blood type with disease severity (6). A Danish study identified ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19 (7).

We examined the association of rs17775810 genotypes with the survival of COVID-19 patients. We found that individuals homozygous for the rs17775810 minor allele (TT) have a lower death rate. This result is consistent with another study on SARS-CoV that examined the effect of a polymorphism in CLEC4M, which encodes L-SIGN, a SARS-CoV binding receptor (8). It was shown that homozygosity for CLEC4M tandem repeats played a protective role in SARS coronavirus infection. This effect was not observed in heterozygotes (9).

It has been shown that fluvoxamine can prevent clinical deterioration of COVID-19 patients (1). It is not known whether this effect of fluvoxamine is due to actions on immune cells versus other types of cells. There are in fact several different hypothesized mechanisms by which fluvoxamine might act. Some involve S1R receptor binding, but others do not (8, 10-14).

Our rs17775810 analysis suggests that the favorable effect of fluvoxamine on survival, as reported by Lenze et al. (1), may be mediated through S1R receptor.
References

1. Lenze EJ, Mattar C, Zoromski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS and Reiersen AM: Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: A randomized clinical trial. JAMA 324(22): 2292-2300, 2020. PMID: 33180997. DOI: 10.1001/jama.2020.22760

2. Atkins JL, Masoli JA, Delgado J, Pilling LC, Kuo C-L, Kuchel GA and Melzer D: Preexisting comorbidities predicting covid-19 and mortality in the uk biobank community cohort. J Gerontol A Biol Sci Med Sci 75(11): 2224-2230, 2020. PMID: 32687551. DOI: 10.1093/gerona/lla183

3. Gregiani E, Pallafacchiona G, Zanin S, Crippa V, Rusmini P, Poletti A, Fang M, Li Z, Bianco V, Petrucci A, Lispi T, Cavallaro T, Fabrizi GM, Muglia M, Boaretto F, Vettori A, Rizzuto R, Mostaccioulo ML and Vazza G: Loss-of-function mutations in the sigm1 gene cause distal hereditary motor neuropathy by impairing er-mitochondria tethering and ca2+ signalling. Hum Mol Genet 25(17): 3741-3753, 2016. PMID: 27402882. DOI: 10.1093/hmg/ddw220

4. Zhu A, Salminen LE, Thompson PM and Jahanshad N: The uk biobank dataparser: A tool with built-in and customizable filters for brain studies. Organization for Human Brain Mapping. Rome, Italy, June 9-13, 2019.

5. Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Alibillas A, Invernizzi P, Fernandez J, Prati D, Basili G, Asselta R, Grimsmud MM, Milani C, Aziz F, Kassens J, May S, Wendoff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yingling M, Avidan MS and Schnitzler A: Preexisting comorbidities predicting severe covid-19 with respiratory failure. NEJM 383(16): 2388-2400, 2020. PMID: 33180997. DOI: 10.1056/NEJMoa2020265

6. Kaiser J: Found: Genes that sway the course of the coronavirus. Science 370(6514): 275-276, 2020. PMID: 33060342. DOI: 10.1126/science.370.6514.275
Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH, Jr., Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D, Consortium QSB, Hodder AJ, Shun-Shion AS, Williams DM, White KM, Rosales R, Kehrer T, Miorin L, Moreno E, Patel AH, Rihn S, Khalid MM, Vallejo-Gracia A, Fozouni P, Simonneau CR, Roth TL, Wu D, Karim MA, Ghoussaini M, Dunham I, Berardi F, Weigang S, Chazal M, Park J, Logue J, McGrath M, Weston S, Haupt R, Hastie CJ, Elliott M, Brown F, Burness KA, Reid E, Dorward M, Johnson C, Wilkinson SG, Geyer A, Giesel DM, Baillie C, Raggett S, Leech H, Toth R, Goodman N, Keough KC, Lind AL, Zoonomia C, Klesh RJ, Hemphill KR, Carlson-Stevermer J, Oki J, Holden K, Maures T, Pollard KS, Sali A, Agard DA, Cheng Y, Fraser JS, Frost A, Jura N, Kortemme T, Manglik A, Southworth DR, Stroud RM, Alessi DR, Davies P, Frieman MB, Ideker T, Abate C, Jouve net N, Kochs G, Shoichet B, Ott M, Palmarini M, Shokat K, Garcia-Sastre A, Rassen JA, Grosse R, Rosenberg OS, Verba KA, Basler CF, Vignuzzi M, Peden AA, Beltrao P and Krogan NJ: Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370(6521): eabe9403, 2020. PMID: 33060197. DOI: 10.1126/science.abe9403

13 Pandey P, Prasad K, Prakash A and Kumar V: Insights into the biased activity of dextromethorphan and haloperidol towards sars-cov-2 nsp6: In silico binding mechanistic analysis. J Mol Med (Berl) 98(12): 1659-1673, 2020. PMID: 32965508. DOI: 10.1007/s00109-020-01980-1

14 Nicol GE, Karp JF, Reiersen AM, Zorumski CF and Lenze EJ: "What were you before the war?" Repurposing psychiatry during the covid-19 pandemic. J Clin Psychiatry 81(3): 20com13373, 2020. PMID: 32271506. DOI: 10.4088/JCP.20com13373

15 Lovkvist H, Jonsson AC, Luthman H, Jood K, Jern C, Wieloch T and Lindgren A: Variations in apolipoprotein d and sigma non-opioid intracellular receptor 1 genes with relation to risk, severity and outcome of ischemic stroke. BMC Neurol 14: 191, 2014. PMID: 25261976. DOI: 10.1186/s12883-014-0191-2

Received December 14, 2020
Revised December 31, 2020
Accepted January 14, 2021